Skip to Content
 
Center for International Blood and Marrow Transplant Research

GV14-01a

Main Content

Comparison of mycophenolate versus methotrexate in combination with a calcineurin inhibitor for graft-versus-host disease prophylaxis in myeloablative allogeneic hematopoietic cell transplantation.

Study #: GV14-01a

Study Status: Published

Presentation(s)

2018, Tandem (Poster)

Comparative analysis of calcineurin inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation.

Citation

Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn J-Y, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK.

Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2019, Jan 01: 25(1): 25(1):73-85. doi: 10.1016/j.bbmt.2018.08.018. Epub 2018, Aug 25. PMCID:PMC6355336.

PubMed

PMID: 30153491

Abstract